尼拉帕利联合最佳支持治疗用于一线铂类化疗后未进展的晚期尿路上皮癌患者的维持治疗:Meet-URO12随机2期试验
Meet-URO12是一项随机、多中心、开放标签2期试验,纳入一线铂类化疗4至6周期后无进展的晚期尿路上皮癌患者,按2:1随机接受尼拉帕利联合最佳支持治疗或单纯最佳支持治疗。尼拉帕利组与对照组的PFS分别为2.1个月和2.4个月(HR 0.92,95%CI 0.49-1.75,p=0.81),6个月无进展率分别为28.2%和26.3%。
要点
- 尼拉帕利联合最佳支持治疗未显著改善一线铂类化疗后无进展晚期尿路上皮癌患者的无进展生存。
- 尼拉帕利组中位PFS为2.1个月,对照组为2.4个月(HR 0.92,95%CI 0.49-1.75,p=0.81)。
- 尼拉帕利组常见不良事件包括贫血(50%,G3 11%)、血小板减少(37%,G3-4 16%)和中性粒细胞减少(21%,G3 5%)。
核心结论
- 在晚期尿路上皮癌患者一线铂类化疗后,尼拉帕利联合最佳支持治疗较单纯最佳支持治疗未显著改善无进展生存。
- 作者认为这些结果不支持在该人群中开展单药尼拉帕利的3期试验。
研究设计与样本
- Meet-URO12为随机、多中心、开放标签2期试验,共随机58例患者(A组39例,B组19例)。
- 纳入标准为晚期尿路上皮癌、一线铂类化疗4至6周期后无疾病进展、ECOG体能状态0或1,入组时间为2019年8月至2021年3月。
- 随机按ECOG体能状态(0/1)和铂类化疗疗效(客观缓解/疾病稳定)分层,按2:1随机分配。
主要发现
- 尼拉帕利组(A组)中位PFS为2.1个月,对照组(B组)为2.4个月(HR 0.92,95%CI 0.49-1.75,p=0.81)。
- 6个月无进展率在A组为28.2%,在B组为26.3%。
- 患者中位年龄69岁,ECOG体能状态0分者占66%、1分者占34%,化疗最佳疗效为客观缓解者占55%、疾病稳定者占45%。
- 尼拉帕利组最常见不良事件为贫血(50%,G3 11%)、血小板减少(37%,G3-4 16%)、中性粒细胞减少(21%,G3 5%)、乏力(32%,G3 16%)、便秘(32%,G3 3%)、黏膜炎(13%,G3 3%)和恶心(13%,G3 3%)。
关键数值与推荐
- A组(尼拉帕利300 mg或根据体重和基线血小板使用200 mg每日一次,联合最佳支持治疗)vs B组(单纯最佳支持治疗):中位PFS 2.1个月 vs 2.4个月(HR 0.92,95%CI 0.49-1.75,p=0.81)。
- A组 vs B组:6个月无进展率28.2% vs 26.3%。
临床怎么用
- 作者认为这些结果不支持在该人群中开展单药尼拉帕利的3期试验。
局限性
- 主要局限性为样本量小:2021年3月维持治疗阿维鲁单抗在同一适应症获批,使对照组仅接受最佳支持治疗的随机化不符合伦理,入组提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Platinum-based chemotherapy (PBCT) is the standard first-line treatment for advanced urothelial carcinoma (UC). Potential cross-sensitivity can be hypothesized between platinum drugs and poly-ADP ribose-polymerase (PARP) inhibitors. OBJECTIVE: To compare maintenance treatment with the PARP inhibitor niraparib plus best supportive care (BSC) versus BSC alone in patients with advanced UC without disease progression after first-line PBCT. DESIGN, SETTING, AND PARTICIPANTS: Meet-URO12 is a randomized, multicenter, open-label phase 2 trial. Patients with advanced UC, without disease progression after four to six cycles of PBCT, with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, were enrolled between August 2019 and March 2021. Randomization was stratified by ECOG performance status (0/1) and response to PBCT (objective response/stable disease). INTERVENTION: Patients were randomized (2:1) to experimental arm A (niraparib 300 or 200 mg daily according to body weight and baseline platelets, plus BSC) or control arm B (BSC alone). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was progression-free survival (PFS). The analysis was performed on an intention-to-treat basis. The secondary endpoints reported in this primary analysis are progression-free rate at 6 mo and safety (adverse event rate). RESULTS AND LIMITATIONS: Fifty-eight patients were randomized (39 in arm A and 19 in arm B). The median age was 69 yr, ECOG performance status was 0 in 66% and 1 in 34%; and the best response with chemotherapy was objective response in 55% and stable disease in 45%. The median PFS was 2.1 mo in arm A and 2.4 mo in arm B (hazard ratio 0.92; 95% confidence interval 0.49-1.75, p = 0.81). The 6-mo progression-free rates were 28.2% and 26.3%, respectively. The most common adverse events with niraparib were anemia (50%, grade [G]3 11%), thrombocytopenia (37%, G3-4 16%), neutropenia (21%, G3 5%), fatigue (32%, G3 16%), constipation (32%, G3 3%), mucositis (13%, G3 3%), and nausea (13%, G3 3%). The main limitation of the study is the small sample size: in March 2021, approval of maintenance avelumab for the same setting rendered randomization of patients in the control arm to BSC alone unethical, and accrual was stopped prematurely. CONCLUSIONS: Addition of maintenance niraparib to BSC after first-line PBCT did not demonstrate a significant improvement in PFS in patients with UC. These results do not support the conduction of a phase 3 trial with single agent niraparib in this population. PATIENT SUMMARY: In this trial, we tested the efficacy of niraparib as maintenance treatment in patients affected by advanced urothelial cancer after the completion of first-line chemotherapy. We could not demonstrate a significant improvement in progression-free survival with maintenance niraparib.
引用
- Vignani F, Tambaro R, De Giorgi U, et al. Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial. Eur Urol. 2022. PMID: 36216658. doi:10.1016/j.eururo.2022.09.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。